These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 2572254)

  • 1. Focus on diastolic dysfunction: a new approach to heart failure therapy.
    Pouleur H; Hanet C; Gurné O; Rousseau MF
    Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):41S-52S. PubMed ID: 2572254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beta, partial agonists to treat heart failure: effects of xamoterol upon cardiac function and clinical status.
    Heng MK
    Clin Cardiol; 1990 Mar; 13(3):171-6. PubMed ID: 1969783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical experience of therapy with xamoterol in patients with severe systolic and diastolic dysfunction.
    Pouleur H; Hanet C; Rousseau MF
    Eur Heart J; 1990 Apr; 11 Suppl A():33-8. PubMed ID: 1971587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term studies with xamoterol in heart failure.
    Waller DG
    Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):53S-58S. PubMed ID: 2572255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Role of adrenergic beta receptor partial agonists in left ventricular failure of ischemic origin. Value of xamoterol (ICI 118,587, Corwin)].
    Rousseau MF; Cheron P; Nannan M; Vincent MF; Lavenne F; Pouleur H
    Ann Med Interne (Paris); 1985; 136(3):247-50. PubMed ID: 2862823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Xamoterol, a beta 1-adrenoceptor partial agonist: review of the clinical efficacy in heart failure.
    Marlow HF
    Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):23S-30S. PubMed ID: 2572251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacology of xamoterol: a basis for modulation of the autonomic control of the heart.
    Snow HM
    Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):3S-13S. PubMed ID: 2572252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The management of heart failure and the scope for new therapies: what role for xamoterol?
    Campbell RW
    Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):59S-64S. PubMed ID: 2572256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of xamoterol on resting and exercise haemodynamics in patients with chronic heart failure.
    Virk SJ; Davies MK
    Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):15S-22S. PubMed ID: 2572250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of left ventricular contractility and relaxation with the beta 1-adrenergic receptor partial agonist xamoterol at rest and during exercise in patients with postinfarction left ventricular dysfunction. A placebo-controlled randomized trial.
    de Feyter PJ; Serruys PW; Suryapranata H
    Circulation; 1990 Feb; 81(2 Suppl):III99-106. PubMed ID: 1967562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical aspects of left ventricular diastolic function assessed by Doppler echocardiography following acute myocardial infarction.
    Poulsen SH
    Dan Med Bull; 2001 Nov; 48(4):199-210. PubMed ID: 11767125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relation of diastolic function and exercise capacity in ischemic left ventricular dysfunction. Role of beta-agonists and beta-antagonists.
    Pouleur H; Hanet C; Rousseau MF; van Eyll C
    Circulation; 1990 Aug; 82(2 Suppl):I89-96. PubMed ID: 1973644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effects of xamoterol on left ventricular diastolic function and late remodeling: a study in patients with anterior myocardial infarction and single-vessel disease.
    Pouleur H; van Eyll C; Hanet C; Cheron P; Charlier AA; Rousseau MF
    Circulation; 1988 May; 77(5):1081-9. PubMed ID: 2896076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the beta 1-adrenergic receptor partial agonist xamoterol on left ventricular diastolic function. An evaluation after 1-6 years of oral therapy.
    Pouleur H; Etienne J; Van Mechelen H; Gurné O; Rousseau MF
    Circulation; 1990 Feb; 81(2 Suppl):III87-92. PubMed ID: 1967560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Acute effect of the cardioselective beta-1-partial agonist, Corwin, on ventricular function and myocardial oxygen consumption in patients with dilated cardiomyopathy].
    Amende I; Simon R; Hood WP; Lichtlen PR
    Z Kardiol; 1986 May; 75(5):291-5. PubMed ID: 2874668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective beta-1-adrenoceptor partial agonist treatment for congestive heart failure.
    Shabetai R
    Cardiology; 1990; 77(5):357-66. PubMed ID: 1981492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of chronic oral administration of xamoterol to patients with severe heart failure treated with ACE inhibitors.
    Pouleur H; Hanet C; Rousseau MF
    Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):82S-83S. PubMed ID: 2572263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of clinical experience with xamoterol. Effects on exercise capacity and symptoms in heart failure.
    Marlow HF
    Circulation; 1990 Feb; 81(2 Suppl):III93-8. PubMed ID: 1967561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Xamoterol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.
    Furlong R; Brogden RN
    Drugs; 1988 Oct; 36(4):455-74. PubMed ID: 2906865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effects of dobutamine and corwin, a beta 1-adrenergic partial agonist, in experimental left ventricular failure.
    Vik-Mo H; Yasay G; Maroko PR; Ribeiro LG
    J Cardiovasc Pharmacol; 1985; 7(4):784-90. PubMed ID: 2410722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.